In spite of the presented possible biomarker capabilities, it becomes apparent that aberrant DNA methylation of PITX2 variants is not as prognostic for BTCs as it is for breast or prostate cancer [17,35]. This evidence concerns the gene PITX2 and Familial prostate cancer.